Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine

Vaccination against SARS-CoV-2 is considered as the most important preventive strategy against COVID-19, but its efficacy in patients with hematological malignancies is largely unknown. We investigated the development of neutralizing antibodies (NAbs) against SARS-CoV-2 in patients with Waldenstrom...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Exp Med
Päätekijät: Gavriatopoulou, Maria, Terpos, Evangelos, Kastritis, Efstathios, Briasoulis, Alexandros, Gumeni, Sentiljana, Ntanasis-Stathopoulos, Ioannis, Sklirou, Aimilia D., Malandrakis, Panagiotis, Eleutherakis-Papaiakovou, Evangelos, Migkou, Magdalini, Trougakos, Ioannis P., Dimopoulos, Meletios A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer International Publishing 2021
Aiheet:
Short Communication
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8290394/
https://ncbi.nlm.nih.gov/pubmed/34283338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10238-021-00746-4
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia